MX343327B - Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. - Google Patents

Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.

Info

Publication number
MX343327B
MX343327B MX2013009570A MX2013009570A MX343327B MX 343327 B MX343327 B MX 343327B MX 2013009570 A MX2013009570 A MX 2013009570A MX 2013009570 A MX2013009570 A MX 2013009570A MX 343327 B MX343327 B MX 343327B
Authority
MX
Mexico
Prior art keywords
tnfa
assays
present
autoantibodies
detecting autoantibodies
Prior art date
Application number
MX2013009570A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009570A (es
Inventor
Singh Sharat
Long Wang Shui
Ohrmund Linda
Hauenstein Scott
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013009570A publication Critical patent/MX2013009570A/es
Publication of MX343327B publication Critical patent/MX343327B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013009570A 2011-02-17 2012-02-16 Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. MX343327B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444097P 2011-02-17 2011-02-17
US201161484594P 2011-05-10 2011-05-10
US201161496501P 2011-06-13 2011-06-13
PCT/US2012/025437 WO2012154253A1 (en) 2011-02-17 2012-02-16 ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS

Publications (2)

Publication Number Publication Date
MX2013009570A MX2013009570A (es) 2013-09-06
MX343327B true MX343327B (es) 2016-11-01

Family

ID=45809635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009570A MX343327B (es) 2011-02-17 2012-02-16 Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.

Country Status (17)

Country Link
US (1) US20140045276A1 (he)
EP (1) EP2676137B1 (he)
JP (1) JP6063398B2 (he)
KR (1) KR20140008397A (he)
CN (1) CN103502815B (he)
AU (1) AU2012254150B2 (he)
BR (1) BR112013020981A2 (he)
CA (1) CA2827609A1 (he)
DK (1) DK2676137T3 (he)
ES (1) ES2530175T3 (he)
HK (1) HK1191688A1 (he)
IL (1) IL227853A (he)
MX (1) MX343327B (he)
RU (1) RU2013142278A (he)
SG (1) SG192770A1 (he)
WO (1) WO2012154253A1 (he)
ZA (1) ZA201306950B (he)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
CN104634955B (zh) 2009-10-26 2016-09-14 雀巢产品技术援助有限公司 检测抗-tnf药物和自身抗体的试验
EP2630495B1 (en) 2010-10-18 2017-02-08 Nestec S.A. Methods for determining anti-drug antibody isotypes
KR20140047628A (ko) 2011-07-06 2014-04-22 네스텍 소시에테아노님 Ｔｎｆ알파로의 생물학적 치료요법에 대한 중화 자가항체의 검출을 위한 검정
CN104718453B (zh) * 2012-10-03 2017-03-08 Gyros专利公司 酸性条件下分析物测定用方法和试剂盒
AU2013326070A1 (en) 2012-10-05 2015-04-23 Société des Produits Nestlé S.A. Methods for predicting and monitoring mucosal healing
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
EP2954329A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3077818B1 (en) 2013-12-03 2020-02-05 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
SG10201906750XA (en) 2014-02-11 2019-09-27 Genzyme Corp Assays for detecting the presence or amount of an anti-drug antibody
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN104034896A (zh) * 2014-06-19 2014-09-10 华北制药集团新药研究开发有限责任公司 一种双抗体夹心elisa检测方法
US10690676B2 (en) 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
EP3210016A1 (en) * 2014-10-20 2017-08-30 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
MX2017005156A (es) * 2014-11-05 2017-08-08 Hoffmann La Roche Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.
EP3227683B1 (en) 2014-12-05 2019-04-24 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
AU2016326757B2 (en) 2015-09-24 2022-09-01 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
EP3165922B1 (en) * 2015-11-06 2020-06-17 Promise Proteomics A method for quantifying therapeutic antibodies
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
EP3482199A1 (en) 2016-07-08 2019-05-15 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
JP7060510B2 (ja) * 2016-09-06 2022-04-26 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬
WO2018049001A1 (en) 2016-09-07 2018-03-15 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
EP3681528A4 (en) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF THE APOPTOSIS INHIBITOR OF MACROPHAGES
KR20210041009A (ko) * 2018-08-03 2021-04-14 브리스톨-마이어스 스큅 컴퍼니 항-약물 항체를 검출하는 방법
JP2020115139A (ja) * 2020-03-11 2020-07-30 国立大学法人千葉大学 血管炎の検査方法
CN112362649B (zh) * 2020-11-09 2024-07-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
CN114236139A (zh) * 2021-12-30 2022-03-25 苏州和锐生物科技有限公司 一种TNF-α生物制剂的抗体检测试剂盒、制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5094740A (en) * 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
EP1159003B1 (en) * 1999-03-02 2010-11-17 Centocor, Inc. Anti-tnf alpha antibodies in therapy of steroid resistant asthma
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
EP1330525B1 (en) 2000-10-30 2012-12-05 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
ES2486340T3 (es) 2000-10-30 2014-08-18 The Regents Of The University Of Michigan Ácidos nucleicos y proteínas Nod2
AU2002902A (en) 2000-11-14 2002-05-27 Techlab Inc Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
ES2405405T3 (es) 2001-12-17 2013-05-31 Corixa Corporation Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
AU2003284187B2 (en) 2002-10-25 2009-10-01 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
EP1687447A4 (en) 2003-11-03 2008-04-02 Univ Duke METHODS FOR IDENTIFYING INDIVIDUALS WITH PERIOPERATIVE RISK OF BLEEDING, RENAL DYSFUNCTION OR ICTUS
WO2006004958A2 (en) * 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
JP2007147367A (ja) * 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
WO2008059515A2 (en) 2006-08-01 2008-05-22 Divyank Turakhia A system and method of generating related words and word concepts
CN104198705B (zh) 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
CA2712021A1 (en) * 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2010042031A1 (en) * 2008-10-07 2010-04-15 Gyros Patent Ab Semi-sequential assay for detection of an analyte in a sample
CA2761777A1 (en) 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
ES2627909T3 (es) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
US8408369B2 (en) 2009-09-08 2013-04-02 GM Global Technology Operations LLC Bimetallic brake rotor
JP5819307B2 (ja) 2009-10-20 2015-11-24 ネステク ソシエテ アノニム 発癌性融合タンパク質を検出するための近接媒介性アッセイ
CN104634955B (zh) * 2009-10-26 2016-09-14 雀巢产品技术援助有限公司 检测抗-tnf药物和自身抗体的试验

Also Published As

Publication number Publication date
BR112013020981A2 (pt) 2016-10-11
RU2013142278A (ru) 2015-03-27
KR20140008397A (ko) 2014-01-21
US20140045276A1 (en) 2014-02-13
IL227853A0 (he) 2013-09-30
WO2012154253A1 (en) 2012-11-15
SG192770A1 (en) 2013-09-30
CN103502815A (zh) 2014-01-08
ZA201306950B (en) 2015-04-29
MX2013009570A (es) 2013-09-06
IL227853A (he) 2017-07-31
HK1191688A1 (en) 2014-08-01
EP2676137A1 (en) 2013-12-25
CN103502815B (zh) 2015-09-23
EP2676137B1 (en) 2014-12-31
CA2827609A1 (en) 2012-11-15
JP6063398B2 (ja) 2017-01-18
AU2012254150B2 (en) 2015-08-13
AU2012254150A1 (en) 2013-05-02
ES2530175T3 (es) 2015-02-26
JP2014508930A (ja) 2014-04-10
NZ614170A (en) 2015-04-24
DK2676137T3 (en) 2015-01-19

Similar Documents

Publication Publication Date Title
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
MX2012004877A (es) Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
NZ627443A (en) Biological markers for identifying patients for treatment with vegf antagonists
MX361944B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX345230B (es) Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos.
MX343324B (es) Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
WO2013030578A3 (en) Method for detecting nucleosomes
IL222251A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
MX2015006852A (es) Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
GB201206977D0 (en) An enzyme detection device
EP2573192A4 (en) METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM
WO2015049390A3 (en) Kidney disease biomarker
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
WO2014052685A3 (en) Devices and methods for single cell analysis

Legal Events

Date Code Title Description
FG Grant or registration